Three quarters of flat volume growth, private label pressure at 25-30% penetration, and a 28x multiple pricing in growth that isn't materialising.
I'll be upfront about something: P&G has been one of the names I've recommended most consistently over my career. Tide, Pampers, Gillette, Oral-B — these brands have survived wars, recessions, pandemics, and the rise of private label. I've argued, correctly, that P&G's pricing power makes it the closest thing to a bond with equity upside.
So it doesn't come easily when I say the setup right now makes me uncomfortable. Not panicked. Not bearish exactly. But less confident in the thesis than I've been at any point in the past decade.
P&G's moat has always rested on three pillars: brand recognition, distribution scale, and pricing power. Consumers reach for Tide because they trust it. Retailers stock it because it sells. And P&G raises prices 3-5% annually because consumers don't switch over a few dollars on laundry detergent.
All three pillars are showing stress fractures. Private label penetration in key categories — laundry, diapers, personal care — has reached 25-30% in the US and higher in Europe. Amazon's house brands are taking shelf space that P&G has held for decades. And the post-COVID pricing cycle that boosted margins from 2021-2023 has reached its natural limit. Consumers are trading down. Not everywhere, and not permanently. But enough to flatten volume growth.
TickerXray Report
Get the complete Procter & Gamble report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
Three specific data points are gnawing at me. First, organic volume growth in North America has been flat to slightly negative for three consecutive quarters. P&G has masked this with pricing, but you can only raise prices when volumes are declining for so long before the model breaks.
Second, the GLP-1 obesity drug phenomenon is creating unexpected demand headwinds. I know it sounds odd, but households where one or more members are on weight-loss medications are reducing spending on food-adjacent categories. Smaller portion sizes mean fewer paper towels, less dish soap, fewer diapers as family planning shifts. This is still early innings, but the Bounty and Charmin brands are seeing it in the scanner data. We've been tracking this across consumer staples for six months, and the signal is consistent.
Third, emerging market growth — which P&G has leaned on for the past decade — is decelerating as local competitors in India, Indonesia, and Brazil scale their own distribution networks. We saw Unilever lose share in similar markets five years ago through the same dynamic. P&G isn't immune.
The valuation. That's what worries me most. At 28x forward earnings, P&G is priced for 8-10% annual earnings growth. The company is delivering 2-3%. The gap between expectation and reality has persisted because investors are paying a premium for safety — the 'sleep well at night' premium that consumer staples always command during uncertain periods.
But safety premiums can unwind quickly when the safety itself is questioned. If volume declines become the trend rather than the blip — and three quarters of flat-to-negative data is starting to look like a trend — the multiple compresses. A re-rating from 28x to 22x, which is where P&G traded as recently as 2019, implies 20% downside from current levels. That's not a crash. But for a stock that's supposed to be the boring, reliable part of your portfolio, it's a meaningful drawdown.
The data shows this setup before in consumer staples. The volume deterioration in 2018-2019 across the sector led to a sustained de-rating even though earnings held roughly flat. P&G dropped from $110 to $85 during that period. The current environment feels similar — perhaps more acute given the private label pressure.
I haven't recommended selling P&G outright, and I'm not about to start. The brands are too strong, the dividend too reliable, and the management team too competent for a full exit. But I've trimmed my personal model portfolio weight from 5% to 3%, and I'd advise a similar approach for anyone who has let their P&G position grow through appreciation.
The specific worry is a valuation de-rating from 28x to 22-24x earnings, which would take the stock down 15-20% over the next 12-18 months even as earnings hold flat. That's not a disaster, but it's an opportunity cost when there are better risk-adjusted options in consumer staples — Costco for growth, or moving into healthcare staples like JNJ for a similar yield at a lower multiple.
What would change my mind? Two consecutive quarters of positive organic volume growth in North America. That's the signal. Until I see it, caution is warranted.
Full forensic analysis of Procter & Gamble
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
PG at 21.5x earnings versus KO at 25.5x — both are Dividend Aristocrats, both own irreplaceable brands, but one offers meaningfully better value on a risk-adjusted basis. Head-to-head across five dimensions.
A $2 billion automation programme targeting 200-300 basis points of margin expansion, supply chain diversification reducing single-source dependencies to below 10%, and a 68-year dividend streak that's about to accelerate.
Newmont trades at 18.9x earnings with gold near all-time highs, a 58% operating margin, and a $132 billion market cap. The Risk Desk sees four specific threats that gold bulls are choosing to ignore.